Abstract: Included is a brewing system that utilizes a curved pedestal that allows brewed effluent to drain in a manner that travels toward the center of the curved pedestal to maximize the exposure of the effluent to the organic material used for brewing, while also maximizing yield. The pedestal 112 sits above the lowest effluent level to allow the brewed effluent to drain from the organic material that is used for brewing to maximize the amount of effluent obtained. By allowing the brewed effluent to drain from the organic material, the weight and size of the organic material is reduced, so that the filter bag can be removed from the brewing system without ripping or tearing. The brewing system eliminates the need for a separate mesh bag and allows the effluent to drain without squeezing the filter bag and which would otherwise cause the release of harsh oils and acids, which can also be unsanitary as a result of a user handling the bag filter.

Abstract: The invention relates to a novel group of compounds of Formula (I) or salts thereof: wherein Y, Z1, Z2, R1, R4, R5 and n are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through protein kinase B (PKB) such as cancer. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by PKB using said compounds and methods for preparing compounds of Formula (I).

Abstract: The invention relates to a novel group of compounds of Formula (I) or salts thereof: wherein Y, Z1, Z2, R1, R4, R5 and n are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through protein kinase B (PKB) such as cancer. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by PKB using said compounds and methods for preparing compounds of Formula (I).

Abstract: Disclosed is a brewing system that utilizes a curved pedestal that allows brewed effluent to drain in a manner that travels toward the center of the curved pedestal to maximize the exposure of the effluent to the organic material used for brewing, while also maximizing yield. The pedestal 112 sits above the lowest effluent level to allow the brewed effluent to drain from the organic material that is used for brewing to maximize the amount of effluent obtained. By allowing the brewed effluent to drain from the organic material, the weight and size of the organic material is reduced, so that the filter bag can be removed from the brewing system without ripping or tearing. The brewing system eliminates the need for a separate mesh bag and allows the effluent to drain without squeezing the filter bag and which would otherwise cause the release of harsh oils and acids, which can also be unsanitary as a result of a user handling the bag filter.

Abstract: This disclosure includes systems and methods for actuating hydraulically-actuated devices.

Abstract: This disclosure includes methods for testing hydraulically-actuated devices and related systems. Some hydraulically-actuated devices have a housing defining an interior volume and a piston disposed within the interior volume and dividing the interior volume into a first chamber and a second chamber, where the piston is movable relative to the housing between a maximum first position and a maximum second position in response to pressure differentials between the first and second chambers. Some methods include: (1) moving the piston to the first position by varying pressure within at least one of the first and second chambers such that pressure within the second chamber is higher than pressure within the first chamber; and (2) while the piston remains in the first position: (a) reducing pressure within the second chamber and/or increasing pressure within the first chamber; and (b) increasing pressure within the second chamber and/or decreasing pressure within the first chamber.

Abstract: Some of the present systems include a hydraulic power storage system having an accumulator configured to supply pressurized hydraulic fluid to a hydraulically actuated device to actuate the hydraulically actuated device and a drain in fluid communication with the accumulator and including a valve that is actuatable to drain hydraulic fluid from the hydraulic power storage system such that an internal pressure of the accumulator is reduced and a flow restrictor configured to reduce a flow rate of hydraulic fluid through the valve, a hydraulic pump configured to pressurize the accumulator, a pressure sensor configured to capture data indicative of the internal pressure of the accumulator, and a processor configured to actuate the hydraulic pump to increase the internal pressure of the accumulator if the internal pressure of the accumulator, as indicated in data captured by the pressure sensor, falls below a threshold pressure.

Abstract: The invention relates to a novel group of compounds of Formula (I) or salts thereof: wherein Y, Z1, Z2, R1, R4, R5 and n are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through protein kinase B (PKB) such as cancer. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by PKB using said compounds and methods for preparing compounds of Formula (I).

Abstract: The invention relates to a novel group of compounds of Formula (I) or salts thereof: wherein Y, Z1, Z2, R1, R4, R5 and n are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through protein kinase B (PKB) such as cancer. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by PKB using said compounds and methods for preparing compounds of Formula (I).

Abstract: Pyrimidone compounds of formula (I): are inhibitors of the enzyme Lp-PLA2 and are of use in treating atherosclerosis.

Abstract: The invention relates to a novel group of compounds of Formula (I) or salts thereof: wherein Y, Z1, Z2, R1, R4, R5 and n are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through protein kinase B (PKB) such as cancer. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by PKB using said compounds and methods for preparing compounds of Formula (I).

Abstract: Pyrimidone compounds of formula (I): are inhibitors of the enzyme Lp-PLA2 and are of use in treating atherosclerosis.

Abstract: Pyrimidone compounds of formula (I): are inhibitors of the enzyme Lp-PLA2 and are of use in treating atherosclerosis.

Abstract: DGAT-1 inhibitor compounds of formula (I), pharmaceutically-acceptable salts and pro-drugs thereof are described, together with pharmaceutical compositions, processes for making them and their use in treating, for example, obesity

Abstract: The invention relates to a novel group of compounds of Formula (I) or salts thereof: wherein Y, Z1, Z2, R1, R4, R5 and n are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through protein kinase B (PKB) such as cancer. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by PKB using said compounds and methods for preparing compounds of Formula (I).

Abstract: Pyrimidone compounds of formula (I): are inhibitors of the enzyme Lp-PLA2 and are of use in treating atherosclerosis.

Abstract: DGAT-1 inhibitor compounds of formula (I), pharmaceutically-acceptable salts and pro-drugs thereof are described, together with pharmaceutical compositions, processes for making them and their use in treating, for example, obesity wherein, for example, r is 0 or 1 and X1 is linear (1-3C)alkyl; q is 0 or 1 and X2 is fluoro, chloro or (1-3C)alkyl; Y1 is selected from fluoro, chloro, bromo, cyano, (1-3C)alkyl and (1-2C)alkoxy; n is 0, 1 or 2 and Y2 is fluoro, chloro or (1-3C)alkyl; p is 0, 1 or 2 and Y3 is (1-3C)alkyl or forms a (3-5C)cycloalkyl ring; Z is carboxy or —CONHSO2Me or —CONRbRc wherein Rb and Rc are independently selected, for example, from hydrogen and (1-4C)alkyl or Rb and Rc are linked so as to form a morpholine ring or a (4-6C)heterocyclic ring and when Z is —CONRbRc the Rb and Rc groups may be optionally substituted by carboxy.

Abstract: DGAT-1 inhibitor compounds of formula (1), pharmaceutically-acceptable salts and pro-drugs thereof are described, together with pharmaceutical compositions, processes for making them and their use in treating, for example, obesity wherein, for example, Ring A is optionally substituted 2,6-pyrazindiyl; X is ?0; Ring B is optionally substituted 1,4-phenylene; Y1 is a direct bond or —O—; Y2 is —(CH2)r— wherein r is 2 or 3; n is 0 or n is 1 when Y1 is a direct bond between Ring B and Ring C and when Ring B is 1,4-phenylene and Ring C is (4-6C)cycloalkane; Ring C is optionally substituted (4-6C)cycloalkane, (7-10C)bicycloalkane, (8-12C)tricycloalkane, phenylene or pryidindiyl; L is a direct bond or —O—; p is 0, 1 or 2 and when p is 1 or 2 RA1 and RA2 are each independently hydrogen or (1-4C)alkyl; Z is carboxy or a mimic or bioisostere thereof.

Abstract: DGAT-1 inhibitor compounds of formula (I), pharmaceutically-acceptable salts and pro-drugs thereof are described, together with pharmaceutical compositions, processes for making them and their use in treating, for example, diabetes and obesity wherein, R1, R2, R3, R4, X2, q, Y1, Y2, n, Q and Z are as defined in the description.